Nouveau Life Pharmaceuticals, Inc.

Nouveau Life Pharmaceuticals, Inc.

OOTC:NOUV
0.00
USD
0.00
(0.00%)
-0.02EPS
5.12MMarket Cap

Total Valuation

USD

As of March 31, 2008, Nouveau Life Pharmaceuticals, Inc. carries a market capitalization of 5.12M, placing it among publicly traded companies globally. Its enterprise value stands at 5.18M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap5.12M
Enterprise Value5.18M

Share Statistics

As of March 31, 2008, Nouveau Life Pharmaceuticals, Inc. has 30.11M shares outstanding.

Shares Outstanding30.11M

Valuation Ratios

These figures are as of March 31, 2008.

PB Ratio119.92
P/TBV Ratio-13.51
P/FCF Ratio-225.43
P/OCF Ratio-237.83

Financial Position

As of March 31, 2008, Nouveau Life Pharmaceuticals, Inc. maintains a current ratio of 0.00, meaning it holds 0.0x the short-term assets needed to cover near-term liabilities.

Debt / Equity151.19
Debt / EBITDA-0.27

Financial Efficiency

Over the twelve months ended March 31, 2008, Nouveau Life Pharmaceuticals, Inc. posted a negative return on equity (ROE) of -219.52, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -39.31, reflecting losses generated across the asset base.

Return on Equity (ROE)-219.52
Return on Assets (ROA)-39.31

Income Statement

USD

These figures cover the twelve months ended March 31, 2008. EBITDA reached -235,593.00, while operating income came in at -503,315.00.

Operating Income-503,315.00
Net Income-503,315.00
EBITDA-235,593.00
EBIT-503,315.00
Earnings Per Share (EPS)-0.02

Balance Sheet

USD

As of March 31, 2008, Nouveau Life Pharmaceuticals, Inc. holds 347.00 in cash and equivalents against 64,536.00 in total debt, resulting in a net debt position of 64,189.00. Total book value stands at 42,685.00, with working capital of -899,219.00 providing operational flexibility.

Cash & Cash Equivalents347.00
Total Debt64,536.00
Net Debt64,189.00
Equity (Book Value)42,685.00
Working Capital-899,219.00

Cash Flow

USD

Nouveau Life Pharmaceuticals, Inc. produced -21,516.00 in operating cash flow over the twelve months ended March 31, 2008. After subtracting -1,184.00 in capital expenditures, free cash flow totaled -22,700.00 - equivalent to 0.00 per share.

Operating Cash Flow-21,516.00
Capital Expenditures-1,184.00
Free Cash Flow-22,700.00

Dividends & Yields

These figures cover the twelve months ended March 31, 2008. Free cash flow yield is negative at -0.44: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -0.32, meaning Nouveau Life Pharmaceuticals, Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Shareholder Yield-0.32
FCF Yield-0.44